Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases Dr Amit Ziv (Tel Aviv University, Israel, Meir Medical Center, Israel) and Professor Yosef Uziel (Tel Aviv University, Israel , Meir Medical Center, Israel) join Herman Tam to discuss their recent study which evaluated the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing COVID-19 infection in adolescents with juvenile-onset inflammatory or immune rheumatic diseases compared with controls without immune rheumatic disease. The results that the BNT162b2 mRNA vaccine was similarly effective against COVID-19 infection in adolescents with and without IRD and that immunomodulatory therapy did not affect its effectiveness, can encourage adolescents with IRD to get vaccinated against COVID-19.You can read this article [https://doi.org/10.1093/rheumatology/keac408] in Rheumatology.Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, or tweet us @RheumJnl. Want to read more of our research? Explore Rheumatology and Rheumatology Advances in Practice.